GE Capital

gecapital.com

Every year, the infrastructure that powers our homes, transports our products, heals our loved ones, and keeps our societies moving forward needs a trillion dollars more investment than it gets. GE Capital wants to change that. We believe industry and finance have to speak the same language if you’re going to drive the kind of progress the world needs now. We believe our people understand exactly what it takes to make the world work better every day, everywhere, for everyone.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

VALERITAS RECEIVES COURT APPROVAL OF SALE OF BUSINESS TO ZEALAND PHARMA

PR Newswire | March 20, 2020

news image

Valeritas Holdings, Inc.("Valeritas" or the "Company"), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, today announced that the U.S. Bankruptcy Court for the District of Delaware (the "Court") approved the sale of substantially all of the business to Zealand Pharma A/S (NASDAQ: ZEAL) ("Zealand"), a Denmark-based biotechnology company. The transaction is expected to be completed during the first week of April, subj...

Read More

CANCER PREVENTION PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR CPP-1X/SUL FOR TREATMENT OF FAMILIAL ADENOMATOUS POLYPOSIS

Cancer Prevention Pharmaceuticals, CPP-1X/sul | June 29, 2020

news image

Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for CPP-1X/sul for treatment of adults with familial adenomatous polyposis (FAP). FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. The clinical...

Read More

PCI PHARMA SERVICES ANNOUNCES GLOBAL CLINICAL FOOTPRINT WITH CREATION COE IN WESTERN EUROPE

PCI Pharma Services | July 28, 2020

news image

PCI Pharma Services, a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced a significant milestone in its global clinical footprint with the creation of a new Clinical Center of Excellence (COE) in Western Europe at its Berlin location, a major investment that will represent a new flagship site for customers. This is part of PCI’s global strategy to expand its clinical supply-chain network into continental Europe to complement offerings avail...

Read More

Business Insights

OPTOMED SIGNS AN INDUSTRIAL PARTNERSHIP WITH A FRENCH AI COMPANY OPHTAI

Optomed Oyj | March 21, 2022

news image

Optomed and a French artificial intelligence company OphtAI have signed a commercial collaboration agreement, where both parties sell OphtAI artificial intelligence for screening of most common eye diseases together with Optomed Aurora handheld cameras as a complete solution for eye screening. The agreement is focusing mostly on European countries and Canada, where OphtAI has a strong presence. OphtAI offers artificial intelligence for detection of diabetic retinopathy, glaucoma a...

Read More
news image

VALERITAS RECEIVES COURT APPROVAL OF SALE OF BUSINESS TO ZEALAND PHARMA

PR Newswire | March 20, 2020

Valeritas Holdings, Inc.("Valeritas" or the "Company"), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, today announced that the U.S. Bankruptcy Court for the District of Delaware (the "Court") approved the sale of substantially all of the business to Zealand Pharma A/S (NASDAQ: ZEAL) ("Zealand"), a Denmark-based biotechnology company. The transaction is expected to be completed during the first week of April, subj...

Read More
news image

CANCER PREVENTION PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR CPP-1X/SUL FOR TREATMENT OF FAMILIAL ADENOMATOUS POLYPOSIS

Cancer Prevention Pharmaceuticals, CPP-1X/sul | June 29, 2020

Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for CPP-1X/sul for treatment of adults with familial adenomatous polyposis (FAP). FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. The clinical...

Read More
news image

PCI PHARMA SERVICES ANNOUNCES GLOBAL CLINICAL FOOTPRINT WITH CREATION COE IN WESTERN EUROPE

PCI Pharma Services | July 28, 2020

PCI Pharma Services, a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced a significant milestone in its global clinical footprint with the creation of a new Clinical Center of Excellence (COE) in Western Europe at its Berlin location, a major investment that will represent a new flagship site for customers. This is part of PCI’s global strategy to expand its clinical supply-chain network into continental Europe to complement offerings avail...

Read More
news image

Business Insights

OPTOMED SIGNS AN INDUSTRIAL PARTNERSHIP WITH A FRENCH AI COMPANY OPHTAI

Optomed Oyj | March 21, 2022

Optomed and a French artificial intelligence company OphtAI have signed a commercial collaboration agreement, where both parties sell OphtAI artificial intelligence for screening of most common eye diseases together with Optomed Aurora handheld cameras as a complete solution for eye screening. The agreement is focusing mostly on European countries and Canada, where OphtAI has a strong presence. OphtAI offers artificial intelligence for detection of diabetic retinopathy, glaucoma a...

Read More